echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > [One picture, one drug] Chiglitazar Sodium, a new class 1 diabetes drug, was approved by NMPA for marketing

    [One picture, one drug] Chiglitazar Sodium, a new class 1 diabetes drug, was approved by NMPA for marketing

    • Last Update: 2021-11-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    For more drug research information, pay attention to the investment ecology Chiglitazar Sodium is called Siglitazar Sodium in Chinese.
    It is a new molecular entity independently developed by Shenzhen Microchip Biotechnology Co.
    , Ltd.
    It is a peroxisome proliferator activation.
    Receptor (PPAR) full agonist, which can simultaneously activate the three subtypes of PPAR receptors (α, γ and δ).
    This drug is a class of Sinochem.
    It was approved for marketing by NMPA on October 19, 2021.
    It is a single drug It is suitable for cooperating with diet control and exercise to improve the blood sugar control of adults with type 2 diabetes [1]


    Type 2 diabetes, formerly known as non-insulin-dependent diabetes or adult-onset diabetes, is a chronic metabolic disease that mostly occurs after the age of 35 to 40, and the incidence is increasing.
    The common symptoms are polyuria, polydipsia, polyphagia, and weight.


    The main causes of type 2 diabetes include genetics, environment, life>

    Its notable pathophysiological feature is the decreased ability of insulin to regulate glucose metabolism (insulin resistance) and the decreased insulin secretion (relative decrease) caused by functional defects of pancreatic β-cells

    The prevalence of diabetes in China is mainly type 2 diabetes, which accounts for more than 90% of the diabetic population.
    Type 1 diabetes and other types of diabetes are rare


    The number of male patients is higher than that of female patients, and the proportion of undiagnosed diabetes is higher in cities than in rural areas.
    The prevalence of diabetes in obese and overweight people has increased significantly [3]


    The approval of Chiglitazar Sodium is based on two phase III clinical trials controlled by placebo and sitagliptin.
    The trials included 525 and 740 patients with type 2 diabetes.
    The test results showed that sitagliptin sodium was significantly reduced by 24 The level of glycosylated hemoglobin (HbA1c) at week, 52 weeks decreased by 1.


    In terms of secondary efficacy indicators, Siglipta Sodium showed long-term and sustained effects of lowering fasting blood glucose and 2-hour postprandial blood glucose, and no secondary failure was found in 52 weeks

    In the two experiments, sitaglipta sodium showed significant long-term hypoglycemic effect and good safety.
    Sieglipta sodium also showed good potential in improving insulin resistance, protecting β islet cell function and regulating blood lipids.
    It can prevent and treat type 2 diabetes and its complications in an all-round way, can provide patients with more effective and safe treatment plans, and significantly improve the quality of life of patients [4] 


    For details of Chiglitazar Sodium and the competitive landscape of marketed drugs targeting PPAR-related subtypes for the treatment of type 2 diabetes, see the picture below: (click to enlarge) You can also click the link below to get the corresponding PDF HD version: https://data .
    com/insight/#/ListPdf?tag=2Reference materials 1.
    Drug crossing data https://data.
    Wang Qingxia.
    Progress in clinical treatment of type 2 diabetes[J] .
    China Urban and Rural Enterprise Health,2021,36(09):64-66.
    Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition)(Part 1)[J].
    Chinese Journal of Practical Internal Medicine,2021,41(08):668-695.
    Chipscreen Biosciences announced that the world's first PPAR full agonist sitaglipta sodium for the treatment of type 2 diabetes has been approved for marketing in China: https:// Produced by Cross Data, reprinting without permission is prohibited
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.